Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia

Vaccine

Volumn 32, Issue 51, 2014, Pages 6941-6947

  Deshmukh, Ashish A ^a   Chiao, Elizabeth Y ^b   Das, Prajnan ^a   Cantor, Scott B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anal neoplasia; Cost effectiveness analysis; High grade intraepithelial neoplasia; Human papillomavirus; Quadrivalent human papillomavirus vaccine; Secondary adjunct prevention

Indexed keywords

WART VIRUS VACCINE;

ADULT; ANUS CARCINOMA; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HIDDEN MARKOV MODEL; HIGH GRADE ANAL INTRAEPITHELIAL NEOPLASIA; HISTORY; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT DURATION; VIRAL CLEARANCE; ANUS NEOPLASMS; CARCINOMA IN SITU; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; MALE HOMOSEXUALITY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECURRENT DISEASE; TREATMENT OUTCOME; UTILIZATION; VACCINATION;

ADULT; ANUS NEOPLASMS; CARCINOMA IN SITU; COHORT STUDIES; COST-BENEFIT ANALYSIS; HOMOSEXUALITY, MALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECURRENCE; TREATMENT OUTCOME; VACCINATION;

EID: 84924149251     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.052     Document Type: Article

References (34)

1. Nelson R.A., Levine A.M., Bernstein L., Smith D.D., Lai L.L. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol 2013, 31:1569-1575.
2. Machalek D.A., Poynten M., Jin F., Fairley C.K., Farnsworth A., Garland S.M., et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012, 13:487-500.
3. Gervaz P., Hahnloser D., Wolff B.G., Anderson S.A., Cunningham J., Beart R.W., et al. Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients. J Gastrointest Surg 2004, 8:1024-1030.
4. Goldstone S.E., Kawalek A.Z., Huyett J.W. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 2005, 48:1042-1054.
5. Goldstone R.N., Goldstone A.B., Russ J., Goldstone S.E. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum 2011, 54:1284-1292.
6. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
7. Kim J.J. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10:845-852.
8. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60:1705-1708. Centers for Disease Control and Prevention.
9. Swedish K.A., Factor S.H., Goldstone S.E. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012, 54:891-898.
10. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A., et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012, 344:e1401.
11. Ross C., Ming Y., Pawel P., Michelle C., Elizabeth C., Jennifer W.-C, et al. Baseline data of a phase 3 trial of the quadrivalent HPV vaccine in HIV+ males and females: ACTG 5298. Conference on retrovirus and opportunistic infections (CROI) 2014.
12. Czoski-Murray C., Karnon J., Jones R., Smith K., Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010, 14:iii-iv. ix-x, 1-101.
13. Critchlow C.W., Surawicz C.M., Holmes K.K., Kuypers J., Daling J.R., Hawes S.E., et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995, 9:1255-1262.
14. Palefsky J.M., Holly E.A., Hogeboom C.J., Ralston M.L., DaCosta M.M., Botts R., et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:314-319.
15. Tong W.W., Jin F., McHugh L.C., Maher T., Sinclair B., Grulich A.E., et al. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. AIDS 2013, 27:2233-2243.
16. Hoots B.E., Palefsky J.M., Pimenta J.M., Smith J.S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124:2375-2383.
17. Myers E.R., McCrory D.C., Nanda K., Bastian L., Matchar D.B. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151:1158-1171.
18. Murphy S.L., Xu J., Kochanek K.D. National vital statistics reports 2013, 1-118. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, Hyattsville, MD.
19. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500.e1-500.e7.
20. Goldie S.J., Kuntz K.M., Weinstein M.C., Freedberg K.A., Palefsky J.M. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000, 108:634-641.
21. Consumer price indexes (CPI-U) by major groups: 1990 to 2010 2012, Statistical Abstract of the United States, Bureau of the Census, Washington, DC.
22. Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1172-1177.
23. Briggs A.H., Claxton K., Sculpher M.J. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
24. Koblin B.A., Hessol N.A., Zauber A.G., Taylor P.E., Buchbinder S.P., Katz M.H., et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 1996, 144:916-923.
25. US National Cancer Institute Surveillance, epidemiology, end results (SEER) cancer statistics review 1992-2010.
26. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
27. Rowhani-Rahbar A., Mao C., Hughes J.P., Alvarez F.B., Bryan J.T., Hawes S.E., et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009, 27:5612-5619.
28. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
29. Elbasha E.H., Dasbach E.J. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867.
30. Chin-Hong P.V., Husnik M., Cranston R.D., Colfax G., Buchbinder S., Da Costa M., et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009, 23:1135-1142.
31. National Institute of Health, Broad spectrum HPV (Human Papillomavirus) vaccine study in 16 to 26 year-old women (V503-001 AM2). Accessed on 02/03/2014. http://clinicaltrials.gov/show/NCT00543543.
32. Drolet M., Laprise J.F., Boily M.C., Franco E.L., Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2013, 134:2264-2268.
33. Van de Velde N., Boily M.C., Drolet M., Franco E.L., Mayrand M.H., Kliewer E.V., et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104:1712-1723.
34. Berry J.M., Palefsky J.M., Jay N., Cheng S.C., Darragh T.M., Chin-Hong P.V. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009, 52:239-247.